Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide

BACKGROUND: The objective of this Phase I dose escalation study was to explore the safety and tolerability of eltrombopag, an oral, nonpeptide, thrombopoietin receptor agonist, in patients with advanced soft tissue sarcoma (STS) and thrombocytopenia due to treatment with doxorubicin and ifosfamide (...

Descripción completa

Detalles Bibliográficos
Autores principales: Chawla, Sant P, Staddon, Arthur, Hendifar, Andrew, Messam, Conrad A, Patwardhan, Rita, Kamel, Yasser Mostafa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605142/
https://www.ncbi.nlm.nih.gov/pubmed/23497336
http://dx.doi.org/10.1186/1471-2407-13-121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605142/
https://www.ncbi.nlm.nih.gov/pubmed/23497336
http://dx.doi.org/10.1186/1471-2407-13-121

Ejemplares similares